Cvs Dex-Dox Kids Nighttime Cough Suppressant

Description

CVS Dex Dox Kids Nighttime is a cough suppressant formulated for pediatric use. It is available in a dosage form of liquid, specifically designed for children. The product is packaged in a count of 16 units per box.

Uses and Indications

This drug is indicated for the temporary relief of cough due to minor throat and bronchial irritation, which may occur with a cold. It is also effective in controlling cough to facilitate sleep.

Additionally, this drug provides temporary relief of symptoms associated with hay fever or other upper respiratory allergies, including runny nose, itching of the nose and throat, sneezing, and itchy, watery eyes.

There are no teratogenic or nonteratogenic effects mentioned in the available data.

Dosage and Administration

The recommended dosage for adults and children aged 12 years and older is 2 chewable tablets every 4 hours, with a maximum limit of 12 chewable tablets within a 24-hour period. For children aged 6 to 12 years, the dosage is 1 chewable tablet every 4 hours, not to exceed 6 chewable tablets in a 24-hour period.

It is essential that the tablets are chewed thoroughly before swallowing to ensure proper absorption.

Use of this medication is not recommended for children aged 6 years and under. Healthcare professionals should advise patients to follow these guidelines or any specific instructions provided by their physician.

Contraindications

Use is contraindicated in patients who are consuming alcoholic beverages, as this may increase drowsiness. Additionally, exceeding the recommended dosage is contraindicated due to the potential for adverse effects. Caution is advised when driving a motor vehicle or operating machinery, as drowsiness may impair performance.

Warnings and Precautions

The use of this product is accompanied by specific warnings and precautions that healthcare professionals must consider to ensure patient safety.

It is imperative that this product is not used to induce sleep in children. Additionally, it is contraindicated for patients currently taking a prescription monoamine oxidase inhibitor (MAOI), which includes certain medications prescribed for depression, psychiatric or emotional conditions, or Parkinson's disease. Patients should refrain from using this product for at least two weeks following the discontinuation of an MAOI. If there is uncertainty regarding the presence of an MAOI in a patient's current medication regimen, it is essential to consult a healthcare provider or pharmacist prior to administration.

Healthcare professionals should advise patients to discontinue use and seek medical attention if a cough persists for more than seven days, recurs, or is accompanied by symptoms such as fever, rash, or a persistent headache. These symptoms may indicate a serious underlying condition that requires further evaluation.

No specific emergency medical help instructions or laboratory tests have been provided; however, practitioners should remain vigilant and assess the need for further diagnostic testing based on individual patient circumstances and clinical judgment.

Side Effects

Patients should be aware of several important warnings and recommendations regarding the use of this product. It is contraindicated for use in children for the purpose of inducing sleep. Additionally, patients currently taking a prescription monoamine oxidase inhibitor (MAOI) or who have stopped taking an MAOI within the last two weeks should not use this product. If patients are uncertain whether their prescription medication contains an MAOI, they are advised to consult a healthcare professional.

In the context of over-the-counter (OTC) use, patients should discontinue use and seek medical advice if their cough persists for more than seven days, recurs, or is accompanied by fever, rash, or a persistent headache, as these symptoms may indicate a serious underlying condition.

Before using this product, patients should consult a doctor if they have any of the following conditions: a sodium-restricted diet, glaucoma, difficulty urinating due to an enlarged prostate gland, a breathing problem such as emphysema or chronic bronchitis, a cough accompanied by excessive phlegm, or a persistent or chronic cough associated with smoking, asthma, or emphysema.

Furthermore, patients are encouraged to ask a doctor or pharmacist before use if they are currently taking sedatives or tranquilizers, as interactions may occur.

Drug Interactions

The concomitant use of this medication with monoamine oxidase inhibitors (MAOIs) is contraindicated. Patients should not use this medication while currently taking a prescription MAOI or within two weeks of discontinuing an MAOI. MAOIs are typically prescribed for depression, psychiatric or emotional conditions, and Parkinson's disease.

Additionally, caution is advised when this medication is used in conjunction with sedatives or tranquilizers. Patients are encouraged to consult with a healthcare professional, such as a doctor or pharmacist, prior to use if they are currently taking these types of medications.

The combination of this medication with alcohol, sedatives, or tranquilizers may potentiate drowsiness. Therefore, monitoring for increased sedation is recommended, and dosage adjustments may be necessary based on the clinical response and tolerance of the patient.

Packaging & NDC

Below are the non-prescription pack sizes of Cvs Dex-Dox Kids Nighttime Cough Suppressant (dextromethorphan hbr). Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Pediatric patients under the age of 6 should not use this medication. For children aged 6 to 12 years, the recommended dosage is 1 chewable tablet every 4 hours, with a maximum of 6 chewable tablets in a 24-hour period. In contrast, adults and children aged 12 years and older may take 2 chewable tablets every 4 hours, not exceeding 12 chewable tablets in a 24-hour period.

Healthcare professionals should be aware that excitability may occur, particularly in pediatric patients.

Geriatric Use

Elderly patients may not have specific information regarding the use of this medication, including dosage adjustments, safety concerns, or special precautions. Therefore, healthcare providers should exercise caution when prescribing this medication to geriatric patients. It is advisable to monitor these patients closely for any adverse effects or changes in therapeutic response, given the lack of targeted data for this population.

Pregnancy

Pregnant patients and those who are breastfeeding should consult a healthcare professional prior to using this medication. It is important to assess the potential risks and benefits, as well as any available data regarding fetal outcomes and lactation. Healthcare providers can offer guidance tailored to individual circumstances, ensuring the safety of both the patient and the developing fetus or nursing infant.

Lactation

Lactating mothers are advised to consult a health professional prior to using this medication. There is currently no available data regarding the excretion of this medication in human breast milk or its effects on breastfed infants. Therefore, caution is recommended when administering this medication to lactating mothers.

Renal Impairment

Patients with renal impairment have not been specifically addressed in the available prescribing information. There are no dosage adjustments, special monitoring requirements, or safety considerations outlined for individuals with reduced kidney function. Healthcare professionals should exercise caution and consider the lack of data when prescribing to this patient population.

Hepatic Impairment

Patients with hepatic impairment have not been specifically studied in relation to the use of this medication. Consequently, there are no established dosage adjustments, special monitoring requirements, or precautions outlined for individuals with compromised liver function. It is recommended that healthcare providers exercise caution when prescribing this medication to patients with hepatic impairment, given the lack of data on its safety and efficacy in this population. Regular monitoring of liver function may be prudent in these cases, although specific parameters are not defined in the available information.

Overdosage

In the event of an overdose, it is imperative to seek immediate medical assistance. Healthcare professionals are advised to contact a Poison Control Center at 1-800-222-1222 for guidance on managing the situation effectively.

Prompt intervention is crucial in mitigating potential adverse effects associated with an overdose. Symptoms may vary depending on the substance involved, and healthcare providers should be prepared to assess and manage these symptoms accordingly.

Management procedures may include supportive care and symptomatic treatment, tailored to the specific clinical presentation of the patient. Continuous monitoring and evaluation are essential to ensure patient safety and to address any complications that may arise during the course of treatment.

Nonclinical Toxicology

There is currently no available information regarding teratogenic effects. Similarly, no data has been provided concerning non-teratogenic effects. Additionally, there is no information available in the nonclinical toxicology section. Furthermore, no details have been reported in the context of animal pharmacology and toxicology.

Postmarketing Experience

Postmarketing experience has identified several adverse reactions associated with the use of the product. Reports indicate instances of marked drowsiness and excitability, particularly in pediatric populations. Additionally, there have been observations of increased drowsiness when the product is used concurrently with alcohol, sedatives, or tranquilizers. These events were reported voluntarily or through surveillance programs and are included for informational purposes.

Patient Counseling

Healthcare providers should advise patients to keep this product out of reach of children to prevent accidental ingestion. Patients should be instructed to stop using the product and consult a doctor if their cough persists for more than 7 days, tends to recur, or is accompanied by fever, rash, or a persistent headache, as these symptoms may indicate a serious condition.

When using this product, patients must not exceed the recommended dosage. They should be made aware that marked drowsiness may occur, and excitability may be experienced, particularly in children. It is important to inform patients that the use of alcohol, sedatives, and tranquilizers may enhance drowsiness, and they should avoid alcoholic drinks while using this product. Caution should be exercised when driving a motor vehicle or operating machinery due to the potential for drowsiness.

Patients should be encouraged to consult a doctor before use if they have a sodium-restricted diet, glaucoma, difficulty urinating due to an enlarged prostate gland, or a breathing problem such as emphysema or chronic bronchitis. Additionally, those with a cough accompanied by excessive phlegm (mucus) or a persistent or chronic cough, such as that associated with smoking, asthma, or emphysema, should seek medical advice prior to use. Furthermore, patients taking sedatives or tranquilizers should ask a doctor or pharmacist before using this product.

Storage and Handling

The product is supplied in a package configuration that includes NDC numbers relevant to its identification. It should be stored in a cool, dry place, maintaining a temperature range of 20° to 25°C (68° to 77°F). Proper storage conditions are essential to ensure the integrity and efficacy of the product.

Additional Clinical Information

No further data are available.

Drug Information (PDF)

This file contains official product information for Cvs Dex-Dox Kids Nighttime Cough Suppressant, including active ingredients, dosage, warnings, and labeling as submitted by the manufacturer for OTC distribution.

View product document (PDF)